0 rating


McGill JB, Sloan L, Newman J et al.

Washington University in St. Louis, St. Louis, MO, USA.

 Diabetes Care 2012 Oct 1; Epub ahead of print.

Editor’s note: It can be difficult to obtain tight glycemic control in diabetes patients with severe renal impairment without increasing the risk of severe hypoglycemia. Linagliptin is a dipeptidyl peptidase-4 inhibitor with a non-renal route of excretion, and can be used in patients with varying degrees of renal impairment without dosage reduction.

Return to top


Our most popular articles